DOVPRELA

This brand name is authorized in Austria, Croatia, Estonia, France, Italy, Lithuania, Poland.

Active ingredients

The drug DOVPRELA contains one active pharmaceutical ingredient (API):

1	Pretomanid UNII 2XOI31YC4N - PRETOMANID
	The mechanism of action of pretomanid is thought to involve inhibition of the synthesis of cell wall lipids under aerobic conditions and generation of reactive nitrogen species under anaerobic conditions. Reductive activation of pretomanid by a mycobacterial deazaflavin (F420)-dependent nitro-reductase is required for activity under both aerobic and anaerobic conditions.
	Read more about Pretomanid

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DOVPRELA Tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J04AK08		J Antiinfectives for systemic use → J04 Antimycobacterials → J04A Drugs for treatment of tuberculosis → J04AK Other drugs for treatment of tuberculosis
Discover more medicines within J04AK08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1824746, 1824757, 1824768, 1824779, 1824825, 1840407
FR	Base de données publique des médicaments	63915869
IT	Agenzia del Farmaco	048955013, 048955025, 048955037, 048955049, 048955052
LT	Valstybinė vaistų kontrolės tarnyba	1090966, 1090967, 1090968, 1090969, 1090999
PL	Rejestru Produktów Leczniczych	100439106